Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Envafolimab combined with standard platinum containing dual drug chemotherapy and Recombinant Human Endostatin in patients with advanced (stage IIIB-IV) squamous non-small cell lung cancer.
Squamous Non-small Cell Lung Cancer
DRUG: "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
1 year PFS rate, 12-month progression free survival in ITT population, 12 months after the last subject participating in
ORR, The proportion of subjects with complete response (CR) and partial response (PR) in total subjects, 24 months after the last subject participating in|DOR, DoR (per RECIST 1.1) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first., 24 months after the last subject participating in|PFS, Progression-free survival (PFS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first, 24 months after the last subject participating in|OS, OS is defined as the time from the starting date of study drug to the date of death due to any cause., 24 months after the last subject participating in
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Envafolimab combined with standard platinum containing dual drug chemotherapy and Recombinant Human Endostatin in patients with advanced (stage IIIB-IV) squamous non-small cell lung cancer.